After 168 negotiations and bids lasting for 4 days, 126 new drugs have entered medical insurance, involving multiple treatment fields such as rare diseases, anti-tumor, and chronic diseases. What are the highlights of the new national medical insurance drug catalog? What impact will it have on people's medication? The reporter interviewed relevant experts. 126 kinds of drugs are included in the medical insurance, involving multiple treatment fields. This is another comprehensive upgrade of the "drug basket" of more than 1.3 billion insured people -126 new drugs are included in the medical insurance, including 21 kinds of tumor drugs, 17 kinds of COVID-19 and anti infection drugs, 15 kinds of drugs for chronic diseases such as diabetes and psychosis, and 15 kinds of drugs for rare diseases; At the same time, one drug that is about to be delisted will be recalled. Huang Xinyu, Director of the Department of Medical Service Management of the State Health Insurance Administration, said at the press conference on the 13th that after this adjustment, the total number of drugs in the list will increase to 3088, including 1698 western drugs and 1390 traditional Chinese patent medicines and simple preparations. The security level in the fields of chronic diseases, rare diseases, and children's drug use will be further improved. This adjustment adds 15 drugs for rare diseases outside of the catalog, covering 16 rare disease categories, filling the gap in drug security for 10 disease categories, such as Egeltam Tartrate used for treating adult patients with type I Goscher's disease and Situximab used for treating Castleman's disease. "Single gene inherited diseases are diseases caused by functional abnormalities caused by single gene mutations, accounting for 80% of rare diseases." Qiu Zhengqing, a rare disease research expert and chief pediatrician at Peking Union Medical College Hospital, introduced that spinal muscular atrophy (SMA), Goecher's disease, and other diseases are all single gene inherited diseases. It is important for patients to include these diseases in medical insurance in a timely manner. In addition, escuzumab, which can be used to treat three rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome, and refractory systemic myasthenia gravis, has successfully entered medical insurance. "PNH is a rare acquired hemolytic disease," said Fu Rong, Vice President and Director of the Hematology Center at Tianjin Medical University General Hospital. Compared to the limitations of traditional therapies, the successful entry of escuzumab into medical insurance can enable more patients to receive effective treatment and reduce their burden. "Being able to enter medical insurance means that more patients with rare diseases have hope for medication," said Jin Mei, one of the leaders of the negotiation group of the medical insurance party and deputy director of the Yunnan Provincial Medical Insurance Bureau, who participated in the negotiation. The value and cost of medication for rare diseases are relatively high, and within the acceptable range of the medical insurance fund, efforts should be made to include them in medical insurance. In terms of anti-tumor drugs, the new national medical insurance drug catalog has added Acotinib for the treatment of adult mantle cell lymphoma; It is used to treat breast cancer. Zhu Jun, Secretary of the Party Committee and Chief Physician of the Department of Lymphatic Oncology at Peking University Cancer Hospital, introduced that the newly added drugs can help patients more easily accept and adhere to long-term treatment, and enrolling in medical insurance can also help reduce the financial burden on patients. A batch of innovative drugs have been added to medical insurance under pressure. "In 2023, 25 innovative drugs participated in negotiations, and 23 were negotiated, with a success rate of 92%." Huang Xinyu said that through negotiations, the prices of innovative drugs became more reasonable, patient affordability improved, and most of them experienced an increase in sales and income. After nearly an hour of tug of war negotiations, Baekje